Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Variability in In Vitro OATP1B1/1B3 Inhibition Data: Impact of Incubation Conditions on Variability and Subsequent Drug Interaction Predictions.

McFeely SJ, Ritchie TK, Ragueneau-Majlessi I.

Clin Transl Sci. 2019 Aug 29. doi: 10.1111/cts.12691. [Epub ahead of print]

PMID:
31468718
2.

Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3.

McFeely SJ, Ritchie TK, Yu J, Nordmark A, Levy RH, Ragueneau-Majlessi I.

Clin Transl Sci. 2019 Jul;12(4):379-387. doi: 10.1111/cts.12623. Epub 2019 Mar 12.

3.

Organic anion transporting polypeptide 2B1 - More than a glass-full of drug interactions.

McFeely SJ, Wu L, Ritchie TK, Unadkat J.

Pharmacol Ther. 2019 Apr;196:204-215. doi: 10.1016/j.pharmthera.2018.12.009. Epub 2018 Dec 14. Review.

PMID:
30557631
4.

What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.

Yu J, Zhou Z, Owens KH, Ritchie TK, Ragueneau-Majlessi I.

Drug Metab Dispos. 2017 Jan;45(1):86-108. Epub 2016 Nov 7. Review.

PMID:
27821435
5.

Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design.

Sáfár Z, Vaskó B, Ritchie TK, Imre G, Mogyorósi K, Erdő F, Rajnai Z, Fekete Z, Szerémy P, Muka L, Zolnerciks JK, Herédi-Szabó K, Ragueneau-Majlessi I, Krajcsi P.

Curr Drug Metab. 2016;17(5):430-55. Review.

PMID:
26728264
6.

Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.

Yu J, Ritchie TK, Zhou Z, Ragueneau-Majlessi I.

Drug Metab Dispos. 2016 Jan;44(1):83-101. doi: 10.1124/dmd.115.066720. Epub 2015 Sep 30. Review.

PMID:
26424199
7.

The multidrug resistance pump ABCB1 is a substrate for the ubiquitin ligase NEDD4-1.

Akkaya BG, Zolnerciks JK, Ritchie TK, Bauer B, Hartz AM, Sullivan JA, Linton KJ.

Mol Membr Biol. 2015;32(2):39-45. doi: 10.3109/09687688.2015.1023378. Epub 2015 May 26.

8.

Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.

Lee CA, O'Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-Gliszczynski MJ.

Drug Metab Dispos. 2015 Apr;43(4):490-509. doi: 10.1124/dmd.114.062174. Epub 2015 Jan 13. Review.

PMID:
25587128
9.

Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review.

Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I.

Drug Metab Dispos. 2014 Dec;42(12):1991-2001. doi: 10.1124/dmd.114.060392. Epub 2014 Sep 30. Review.

PMID:
25271211
10.

Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2.

Ritchie TK, Kwon H, Atkins WM.

J Biol Chem. 2011 Nov 11;286(45):39489-96. doi: 10.1074/jbc.M111.284554. Epub 2011 Sep 21.

11.

Chapter 11 - Reconstitution of membrane proteins in phospholipid bilayer nanodiscs.

Ritchie TK, Grinkova YV, Bayburt TH, Denisov IG, Zolnerciks JK, Atkins WM, Sligar SG.

Methods Enzymol. 2009;464:211-31. doi: 10.1016/S0076-6879(09)64011-8.

Supplemental Content

Loading ...
Support Center